i 
 
Protocol version 11 version date 07/13/2020 Title:  Api[INVESTIGATOR_659568] (AREST)  
 
 
Drug or Device 
Name(s):  Api[INVESTIGATOR_659569] : Exempt  
BMS Protocol #  CV185 -370 
IRB Protocol #:  Pro000 [ADDRESS_889551] #  [STUDY_ID_REMOVED]  
 
 
Study Principal Investigator  
[INVESTIGATOR_659570], MD  
Department of Internal Medicine  
Division of Cardiovascular Sciences  
University of South [LOCATION_012]  
 
Study Co -Principal Investigator  
[INVESTIGATOR_659571], MD  
Department of Neurology  
University of South [LOCATION_012]  
  
  
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
ii 
 
Protocol version 11 version date 07/13/[ADDRESS_889552]  ................................................................................................... 11 
2.3 STROKE ADJUDICATION COMMITTEE (SACCO)  ......................................................................................... 11 
2.3.1  Adjudicators .................................................................................................................... 11 
2.3.2  Stroke/TIA Subtype Classification18, 19 ............................................................................ 11 
2.3.3  Examination .................................................................................................................... 12 
2.3.4  Stroke Disability .............................................................................................................. 12 
2.4 ATRIAL FIBRILLATION REVIEW COMMITTEE  .............................................................................................. 12 
2.4.1  Members  .......................................................................................................................... 12 
2.4.2  Atr
ial Fibrillation Classifications and Diagnosis 10 ....................................................... 12 
3 STUDY OBJECTIVES  ................................................................................................................... 13 
3.1 RESEARCH HYPOTHESIS  .............................................................................................................................. 13 
3.2 PRIMARY OBJECTIVE  .................................................................................................................................. 13 
3.3 SECONDARY OBJECTIVES  ............................................................................................................................ 13 
4 INVESTIGATIONAL PLAN ......................................................................................................... 14 
4.1 GENERAL SCHEMA OF STUDY DESIGN  ........................................................................................................ 14 
4.1.1  Screening Phase .............................................................................................................. 15 
4.2 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES .......................................................................... 15 
4.2.1  Duration of Study ............................................................................................................ 15 
4.2.2  Total Number of Study Sites/Total Number of Subjects Pr ojected  .................................. 15 
4.3 STUDY POPULATION  ................................................................................................................................... 15 
4.3.1  Inclusion Criteria ............................................................................................................ 15 
4.3.2  Exclusion Criteria  ........................................................................................................... 17 
4.3.3  Women of Childbearing Potential ................................................................................... 18 
5 STUDY DESIGN AND INT ERVENTION  ................................................................................... 18 
5.1 SCREENING VISIT ........................................................................................................................................ 18 
5.2 BASELINE VISIT/RANDOMIZATION .............................................................................................................. 19 
5.3 TREATMENT PHASE  .................................................................................................................................... 19 
5.4 END OF STUDY  ............................................................................................................................................ 20 
5.5 STUDY ASSESSMENTS (SEE FIGURE 1) ........................................................................................................ 20 
5.6 UNSCHEDULED VISITS  ................................................................................................................................ 20 
5.6.1  Super-therapeutic/Sub- therapeutic INR  .......................................................................... 20 
iii 
 
Protocol version 11 version date 07/13/[ADDRESS_889553] COMPLETION /EARLY WITHDRAWAL  ............................................................................................ 20 
5.8 CONCOMITANT MEDICATION  ...................................................................................................................... 21 
6 STUDY PROCEDURES  ................................................................................................................. 21 
6.1 VISIT 1 SCREENING VISIT/BASELINE /RANDOMIZATION (CAN OCCUR ON SAME DA Y) ................................. 21 
6.2 RANDOMIZATION  ........................................................................................................................................ 21 
6.3 DRUG INITIATION (MAY BE SAME AS RANDOMIZATION DEPENDING ON GROUP AND STUDY AR M) ............... 21 
6.4 TREATMENT VISITS  ..................................................................................................................................... 22 
6.5 END OF STUDY  ............................................................................................................................................ 23 
6.6 EARLY WITHDRAWAL (EW) ....................................................................................................................... 23 
7 STUDY ENDPOINTS AND EVALUATIONS  ............................................................................. 23 
7.1 PRIMARY ENDPOINT  ................................................................................................................................... 23 
7.2 SECONDARY ENDPOINTS  ............................................................................................................................. 24 
7.3 BASELINE EVALUATION (SEE ALSO SCHEDULE OF  EVENTS ) ........................................................................ 24 
7.3.1  Physical Examination ..................................................................................................... 24 
7.3.2  Vital Signs ....................................................................................................................... 24 
7.3.3  Laboratory Evaluations .................................................................................................. 24 
7.4 EFFICACY AND SAFETY EVALUATIONS (SEE ALSO SCHEDULE OF  EVENTS ) .................................................. 24 
7.4.1  Diagnostic Tests, Scales, Measures, etc. ......................................................................... 24 
7.4.2  Safet y criteria for suspension of dosing .......................................................................... 27 
8 STATISTIC AL CONSIDERATIONS  ........................................................................................... 27 
8.1 STATISTICAL METHODS  .............................................................................................................................. 27 
8.1.1  Baseline Data  .................................................................................................................. 27 
8.1.2  Efficacy Analysis/Primary Aim  ....................................................................................... 27  
8.1.3  Safety Analysis/Secondary Aim  ....................................................................................... 28 
8.1.4  Potential Confounders .................................................................................................... 28 
8.1.5  Sample Size and Power. .................................................................................................. 28 
8.1.6  Randomization ................................................................................................................ 29 
8.2 INTERIM ANALYSIS  ..................................................................................................................................... 29 
9 STUDY MEDICATION  ................................................................................................................. 29 
9.1 PACKAGING  ................................................................................................................................................ 29 
9.1.1  Warfarin .......................................................................................................................... 29 
9.1.2  Api[INVESTIGATOR_3822] ......................................................................................................................... 29 
9.2 LABELING  ................................................................................................................................................... 30 
9.3 DOSING  ....................................................................................................................................................... 30 
9.3.1  Warfarin .......................................................................................................................... 30 
9.3.2  Api[INVESTIGATOR_3822]. ........................................................................................................................ 30 
9.4 TREATMENT COMPLIANCE AND ADHERENCE .............................................................................................. 30 
9.5 DRUG ACCO UNTABILITY ............................................................................................................................. 30 
10 SAFETY MANAGEMENT  ............................................................................................................ 31 
10.1 CLINICAL ADVERSE EVENTS  ....................................................................................................................... 31 
10.2 ADVERSE EVENT REPORTING  ..................................................................................................................... 31 
10.3 DEFINITION OF AN ADVERSE EVENT  ........................................................................................................... 31 
10.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) .................................................................................... 31 
10.4.1  Serio
us Adverse Event Collecting and Reporting  ........................................................... 32 
10.4.2  Relationship of SAE to study drug or other intervention ................................................ 33 
10.4.3  Definition of Severity  ...................................................................................................... 34 
10.5 IRB/IEC  NOTIFICATION OF SAE S ............................................................................................................... 34 
10.5.1  SAE Reconciliation ......................................................................................................... 34 
iv 
 
Protocol version 11 version date 07/13/2020 10.5.2  Follow-up report ............................................................................................................. 35 
10.5.3  Non-Serious Adverse Events ........................................................................................... 35 
10.5.4  Non-Serious Event Collecting and Reporting  ................................................................. 35 
10.6 HEALTH  AUTHORITY REPORTING (US  FDA  IND)  ..................................................................................... [ADDRESS_889554] ABNORMALITIES  ......................................................................................................... 36 
10.8 PREGNANCY  ................................................................................................................................................ 36 
10.9 OVERDOSE  .................................................................................................................................................. 36 
10.10  DRUG INDUCED LIVER INJURY (DILI) ........................................................................................................ 36 
10.11  OTHER SAFETY CONSIDERATIONS  .............................................................................................................. 37 
10.12  MEDICAL EMERGENCIES  ............................................................................................................................. 37 
11 STUDY ADMINISTRATION ........................................................................................................ 37 
11.1 TREATMENT ASSIGNMENT METHODS  ......................................................................................................... 37 
11.2 DATA COLLECTION AND MANAGEMENT  ..................................................................................................... 37 
11.2.1  Sources of Materials  ....................................................................................................... 37 
11.3 38 
CONFIDENTIALITY  ........................................................................................................................................................ 38 
11.4 REGULATORY AND ETHICAL CONSIDERATIONS  .......................................................................................... 38 
11.4.1  Risks to subjects  .............................................................................................................. 38 
11.4.2  Pote
ntial Risks  ................................................................................................................ 38 
11.4.3  Risk Assessment ............................................................................................................... 39 
11.4.4  Potential Benefits of Trial Participation  ......................................................................... 39 
11.5 INFORMED CONSENT  ................................................................................................................................... 39 
11.6 PAYMENT TO SUBJECTS /FAMILIES  .............................................................................................................. 39 
11.7 PUBLICATION  .............................................................................................................................................. 39 
12 REFERENCES  ................................................................................................................................ 40 
13 APPENDICES  ................................................................................................................................. 41 
13.1 MODIFIED RANKIN SCALE  .......................................................................................................................... 41 
13.2 NIHSS  ........................................................................................................................................................ 41 
13.3 SS- QOL  ..................................................................................................................................................... 42 
13.4 WARFARIN DOSING PROTOCOL  .................................................................................................................. 46 
 
 
v 
 
Protocol version 11 version date 07/13/2020 ABBREVIATIONS AND DE FINITIONS OF TERMS  
°C  Degrees centigrade  
AE  Adverse event  
AF  Atrial Fibrillation  
ALT  
AST  
aPTT   Alanine aminotransferase  
Aspartate aminotransferase  
Activated Partial Thromboplastin Time  
BMS  
CMP  
CBC  
CK 
CMB   Bristol -Myers Squibb  
Complete metabolic panel  
Complete blood count Creatine kinase  
Cerebral Microbleeds  
CT  
DSMB  
E.G. 
EKG   Computed T omography   
Data and Safety Monitoring Board 
For Example 
Electrocardiogram  
EOS   End of Study  
EW  Early  Withdrawal  
FDA   Food and Drug Administration  
GRE   Gradient Recovery E cho 
INR 
IRB 
LAR   International Normalization Ratio  
Institutional Review Board  
Legally Authorized Representative  
MRI   Magnetic Resonance I maging  
mRS   Modified Rankin Scale  
NIHSS   National Institute of Health  Stroke Scale  
NVAF  
NSAE  
PI  [CONTACT_51584]-Valvular Atrial Fibrillation  
Non Serious Adverse Event 
Princip al Investigator  
SS-QOL   Stroke  Specific  Quality of Life Scale  
SACCO  
 
SWI  Stroke Adjudication Committee for Classification and 
Organization  
Susceptibiltiy Weighted Imaging  
TEE 
TSH   Trans -Esophageal Echocardiogram  
Thyroid Stimulating Hormone  
TIA 
ULN S  Transient Ischemic Attack  
Upper Limit of Normal  
USF  University of South [LOCATION_012]  
WOCBP   Women of Child Bearing Potential  
   
   
   
   
   
   
   
   
   
vi 
 
Protocol version 11 version date 07/13/2020 Schedule of Study Procedures  
TIA -Api[INVESTIGATOR_659572]/  
Baseline  Treatment 
Initiation Maintenance╪ End of 
Study  30day  
PC Early 
Withdrawal  Unsch  
Visit Number  1  2 3 4 5 6 7 8 9 10   
Study Days (Visit Window)  0 β  
(See also 
table 2)  14 (±3) 30(±5) 60(±10
) 90(±10
) 120 (±1
0) 150 (±1
0) 180 
(±10) 210±10
)     
Informed Consent              
Inclusion/Exclusion Criteria              
General Medical 
History/Demographics              
Physical Exam              
Vital Signs§             
mRS              
NIHSS              
SS-QOL              
Urine pregnancy test╪  ╪           
12-lead ECG              
Clinical Lab Evaluation*  **            
PT/INR ( Warfarin arm only)              
TEE †            
Event Monitor (prior to DC)              
Carotid Ultrasound              
MRI or CT scan              
Record AE/SAEs              
Prior and con. medications/procedures              
Dispense Study Drug              
Drug Compliance              
Non-study anticoagulation initiation              
β drug initatiation will be as follows:  TIA: Api[INVESTIGATOR_659573] 0 -3/Warfarin arm day 7 (±5): Small stroke: Api[INVESTIGATOR_659573] 3 -5/Warfarin arm day 14(±5): Medium stroke: Api[INVESTIGATOR_659573] 7 -9/Warfarin arm day 
14(±5) 
* Results of existing tests will be obtained from subject’s hospi[INVESTIGATOR_659574]. If tests results are not avail able labs will be performed at the visit. See section 6 for a detailed description of 
what this entails.    
§ Vitals: BP, HR, , weight,  (RR and Temperature are optional, height obtained at baseline only ) 
 
** Labs for inclusion/exclusion criteria will include CMP, CBC with diff and platelets, Creatinine , PT/INR, LFTs and Lipid panel.  
† performed prior to discharge  
Page vii of 47 
 
Protocol version 11 version date 07/13/2020 ╪ All WOCBP MUST have a negative pregnancy test within  [ADDRESS_889555] be 25 IU/L or equivalent units of HCG. If the pregnancy 
test is positive, the subject must not receive api[INVESTIGATOR_659575] b e enrolled in the study.¥ Study day at screening is day of event  
  Dosing Category  Api[INVESTIGATOR_659576] 0 -3 
Small Stroke  Day 3 -5 
Medium Stroke Day 7 -9 
  Dosing Category Warfarin dose initiation  window  
TIA Day 7  (+/- 5) 
Small Stroke  Day 14  (+/- 5) 
Medium Stroke  Day 14  (+/- 5) 
 
 Table 2  
 
 
    
 
Page 8 of 47  
 
Protocol version 11 version date 07/13/2020 1 BACKGROUND INFORMATION AND RATIONALE  
1.1 Introduction  
Non-Valvular Atrial Fibrillation ( NVAF) is a growing problem with prevalence in the United 
States of  approximately [ADDRESS_889556] 
common cardiac arrhythmia. Patients with AF are at five time’s  greater risk for having a 
stroke  than those in normal sinus rhythm1, 2.  Current clinical practice prohibits  early use of 
anticoagulation following stroke even when etiology is suspected  as embolic3, 4. Furthermore, 
strokes in patients with atrial fibrillation have been shown to be associated with increased 
morbidity and morta lity1, 2. 
Several recent trials with novel anticoagulation  (table 3) have shown stroke prevention 
efficacy equal to or superior to warfarin with over a fifty percent reduction in intracranial 
bleed ; however they excluded subjects with a stroke within seven or less days  5, 6, 7, 8, 9. 
The results from these pi[INVESTIGATOR_659577]:  
 Rely  Rocket AF  Aristotle  Engage  AF 
 Warfarin  Dabigatran  
150mg Warfarin  Rivaroxaban  Warfarin  Api[INVESTIGATOR_659578]  
60mg  
Stroke  
Per year  1.69 %  1.11%  2.2 %  1.7%  1.6%  1.27%  1.50 %  1.18%  
Hemorrhagic 
stroke per 
year 0.38%  0.10%  0.7 %  0.5 %  0.47%  0.24%  0.47%  0.26%  
Major Bleed  
Per year  3.36 %  3.11 %  14.5% * 14.9% * 2.09%  2.13%  3.43 %  2.75 %  
Intracranial  
Bleed Per 
Year  0.74%  0.30% 0.70 %  0.50 %  0.80 % . 0.33 %  0.85 % 0.39 % 
Table 3* total bleed rate accounted for not just major bleed  
This study is being conducted to evaluate if  anticoagulation treatment with Api[INVESTIGATOR_3822], initated 
earlier then the recommended guidelines of within 14 days  after embolic stroke for patients 
with atrial fibrillation is associated with decreased risk for recurrent embolic stroke without 
increasing the risk of hemorrhagic transformation compared to conventional treatment (i.e. no 
anticoagulation treatment within 14 days of stroke10, 11.  
 
1.2 Findings from pre -clinical and clinical studies  
 
Currently, there are limited data regarding the early start of anticoagulation therapy following 
embolic stroke. 
 
In the review of our local stroke database from October 2011 until December 2013, we examined the records of 336 small to medium stroke patients admitted to Tampa General 
Hospi[INVESTIGATOR_659579].  The average age in our study 
population was 75.3 ± 1.83 years of age.  Stroke risk was similar to other AF groups in the 
literature, possessing an average CHADS2 score of 2.6 ± 0.26 on admission; average 
CHA2DS2 -VASc score was 4.4 ± 0.4.  Average hospi[INVESTIGATOR_208141] 9.8 ± 1.49 days.  We 
observed a 24.7% ± 6.2% mortality rate in our population prior to discharge.  In addition, 
stroke survivors had a 5.1% recurrent non- fatal stroke risk.  Patients with disabling or fatal 
Page 9 of 47  
 
Protocol version 11 version date 07/13/2020 strokes were of a more advanced age than those who survived without severe disability (78.0 ± 
1.96 years vs 69.7 ± 3.50 years, p <0.001).Our data indicate  that the risk of fatal to recurrent 
stroke is approximately 2 5 % with standard treatment  (initiating anticoagulation 
approximately seven to fourteen days after signs and symptoms) for this group of patients  12. 
 
The HAEST trial  indicated that low molecular weight heparin results in a reduction in 
mortality and disability when used early ([ADDRESS_889557] stroke) in the treatment of ischemic 
stroke ; however, this benefit is offset by [CONTACT_659623] 3, 13, 1 4  
 
The p revious studies on novel anticoagulation (NOAC)  excluded subjects with a stroke /TIA  
within seven or less days; however, these randomized trials consistently demonstrated a lower 
risk of intracranial bleed compared to traditional anticoagulants  ( see table 2) 5, 6, 7, 8, 9.  
 
ARISTOTLE  followed a limited number of subjects (44) who  suffered a stroke /TIA,  between 
[ADDRESS_889558] reported the use of Da bigatran given within  24 hours of a 
TIA/minor stroke onset in a population of non- AF patients and have found it to demonstrate 
no significant increase in hemorrhagic transformation in this population 
16.  
 Based on these limited data, we propose to examine the potential advant age of  a treatment 
regime n of Api[INVESTIGATOR_350058] [ADDRESS_889559] or Description of Intervention  
17 
Api[INVESTIGATOR_3822], a factor Xa (FXa) inhibitor, is chemically described as 1 -(4-methoxyphenyl)-7-oxo-
6-[4-(2-oxopi[INVESTIGATOR_66808]-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-
carboxamide. Its molecular formula is C25H25N5O4, which corresponds to a molecular weight of 459.5. Api[INVESTIGATOR_659580]: 
 
 
 
  
Api[INVESTIGATOR_34212] a white to pale-yellow powder. At physiological pH (1.2–6.8), api[INVESTIGATOR_659581]; its aqueous solubility across the physiological pH range is ~0.04 mg/mL 17. 
This stud y is a n open label , randomized,  active controlled pi[INVESTIGATOR_659582], within 48 hours from signs and symptoms, been diagnosed with a TIA 
or a Small to Medium Ischemic Stroke as defined  by [CONTACT_659624] (see section 2.3 ) .  
Page 10 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889560] had a recent small or medium stroke or  TIA 
(within 0 -48 hours)  will receive Api[INVESTIGATOR_334427] a day for 180 days with drug initiation day 0-
3 (TIA) , day 3-5(small stroke)  or day 7- 9 (medium stroke)  respectively  or receive standard of 
care warfarin starting at day 7 ±5 (TIA) or day 14 ±5   (small to medium ischemic stroke).  
1.[ADDRESS_889561] any 2 of the following characteristics:  
 • age  ≥80 years 
• body weight ≤60 kg 
• serum creatinine ≥1.5 mg/dL 
 
 
Coadministration with CYP3A4 and P-glycoprotein inhibitors: For patients receiving  
Api[INVESTIGATOR_3822] 5 mg twice daily when Api[INVESTIGATOR_659583] P450 3A4 (CYP3A4) and P-glycoprotein (P- gp) (e.g., ketoconazole, 
itraconazole, ritonavir, clarithromycin), the recommended dose is 2.5 mg twice daily [ patients already taking 2.[ADDRESS_889562] of care arm will be on Warfarin which will be locally sourced and commercial drug supply provided by [CONTACT_69052]. See appendix 13.4 for dosing guidelines. 
 
 
1.5 Compliance Statement  
This study will be conducted in full accordance with  all applicable Institutional Policies  of 
participating sites  and Procedures and all applicable Federal and state laws and regulations 
including 45 CFR 46, 21 CFR Parts 50, 54, 56, 312, 314 and 812 and the Good Clinical 
Practice: Consolidated Guideline approved by [CONTACT_5787] 
(ICH). Any epi[INVESTIGATOR_23457]. 
The investigators will perform the study in accordance with this protocol, will obtain consent, 
and will report adverse events in accordance with IRB Policies and Procedures and all federal 
requirements. Collection, recording, and reporting of data will be accurate and will ensure the 
privacy, health, and welfare of research subjects du ring and after the study.  
 [ADDRESS_889563] quality. The 
Executive Committee will monitor progress of study enrollment, make recommendations in 
collaboration with the sponsor based on the Stroke Adjudication Committee and DSMB Committee input, and oversee the presentation and publication of the trial results. The committe e will convene regularly by [CONTACT_369390]/or face- to-face meetings to discuss 
and report on the ongoing conduct of the study in collaboration with the sponsor. The chairman of the Executive Committee will serve as the third member to both the stroke 
adjudication and a trial fibrillation committees to meet consensus if necessary.  
Page 11 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889564] and is required to provide 
recommendations about continuing, and stoppi[INVESTIGATOR_10098]. In addition, the DSMB is asked to 
make recommendations, as appropriate, about the b enefit/risk ratio of procedures and 
participant burden  
The DSMB will convene annually and at the milestones of  40 and 80 patients  enrolled as well as at study conclusion to review safety data.  
  
Notification of and referral for abnormal findings Data will be collected by [CONTACT_5051]. 
Study data will be entered into the data collection forms or recorded electr onically as they are 
collected during the study visit. The PIs will monitor all data for any inconsistencies or irregularity. If unanticipated adverse events or SAE  of importantce (symptomatic hemorrhagic 
transformation)  are observed, they will be reported to the DSMB within 24 hours . All other  
AE’s will be  reported during scheduled meetings and to the IRB according to standard AE 
reporting policies. The Princip al Investigator will forward all decisions to the regulatory 
authority as appropriate.  
2.3 Stroke A djudication Committee  (SACCO)  
The Stroke Adjudication Committee will review and adjudicate all stroke endpoints. The 
committee will  not be blinded to patient and study medication arm during the review of each 
stroke endpoint case.  
2.3.1 Adjudicators  
W. Scott Burgin, MD  
David Z. Rose, MD Swetha Renati, MD  
Department of Neurology 
University of South [LOCATION_012] 
Ryan Murtagh, MD 
Department of Radiology 
             University of South [LOCATION_012]  
2.3.2 Stroke/TIA Subtype Classification
18, 1 9 
[IP_ADDRESS]  Ischemic Stroke  
Defined as an acute symptomatic focal cerebral or retinal dysfunction caused by [CONTACT_659625].  
1. a. Acute infarcts are classified as small, medium or large based on size of the largest ischemic lesion:  
a. small  = lesion in the anterior or posterior circulation <1.5 cm.  
b. medium = equal to or greater than 1.5cm but less than a complete territory 
infarct lesion in a cortical superficial branch of the anterior cerebral artery 
(ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA), or 
in a branch of MCA or PCA, or lesion in internal border- zone territories.  
c. large posterior  = lesion involving complete PCA territory,  or lesion of 
cerebellum 1.5 cm or larger or any lesion of the brain stem. 
Page 12 of 47  
 
Protocol version 11 version date 07/13/2020 d. large anterior  = lesion involving complete ACA or MCA territory , or 
lesion involving >[ADDRESS_889565] lesion size  
with preferred sequencing to be GRE on MRI ( but all effort should be 
used to maintain the same modality of sequencing and magnet streng th 
used at baseline  
2.Subacute/chronic or 'old' infarcts (i.e. more than 2 weeks) are noted but not 
classified.  
3.Transient Ischemic Attack (TIA)  
defined as an acute symptomatic focal cerebral, spi[INVESTIGATOR_1304], or retinal dysfunction 
in which symptoms resolve (typi [INVESTIGATOR_659584] 1 day) without acute 
damage on neuroimaging. 
 
[IP_ADDRESS]  Hemorrhagic Stroke 
Defined as an acute symptomatic focal or global cerebral dysfunction caused by a 
nontraumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage; or 
asymptomati c neuroimaging -positivity, including greater than three cerebral  
microbleeds found with GRE -sequenceing and/or CT hyperintensities 
[IP_ADDRESS]  Undetermined Stroke  
Undetermined stroke is defined as a stroke with insufficient information to allow categorization as A or B.  
2.3.3 Examination 
Outpatient (in clinic) or Inpatient (in hospi[INVESTIGATOR_307]) physical neuro -examination at day 14, 30, 
60, 90, 120, 150 and 180 
2.3.4 Stroke Disability  
Stroke disability should be measured by a reliable and valid scale in all cases, 
modified Rankin Scale (mRS) and NIHSS  at day 14, 30, 60, 90, 120, 150 and 180 
(see appendix 13.1 and 13.2) 
2.4 Atrial Fibrillation Review Committee  
The Atrial Fibrillation Adjudication Committee will provide Atrial Fibrillation Classifications and Diagnosis prior to randomization  on subjects with new onset 
atrial fibrillation  if the local PI [INVESTIGATOR_659585]. All patients will be 
reviewed by [CONTACT_659626].  
2.4.1 Members  
Michael Fradley, MD  
Department of Cardiovascular Sciences  
University of South [LOCATION_012]  
2.4.2 Atrial Fibrillation Classifications  and Diagnosis 10 
[IP_ADDRESS]  Definition  
a. Non Valvular Atrial fibrillation ( NVAF ) is defined as a supraventricular 
tachyarrhythmia with rapid, uncoordinated atrial electrical activity and 
irregular ventricular responses in the presence of intact atrioventricular (AV) 
conduction.  ECG, Holter, telemetry, or event monitor characteristics include: 
Page 13 of 47  
 
Protocol version 11 version date 07/13/2020 1) irregular R -R intervals (when AV conduction is present), 2) absence of 
distinct repeating P waves, and 3) irregular atrial activity . 
b.  Premature atrial contractions (PACs) with underlying sinus rhythm or 
organized atrial supraventricular tachyarrhythmias such as atrial tachycardia 
or atrial flutter will not constitute a diagnosis of AF  
[IP_ADDRESS]  Classification  
a. Paroxysmal  – Atrial fibrillation that terminates spontaneously or with intervention 
within seven days of onset. Epi[INVESTIGATOR_659586] f requency.  
b. Persistent  – Atrial fibrillation that is sustained for more than 7 days.  Epi[INVESTIGATOR_659587].  
c. Long -standing persistent  – Atrial fibrillation that has lasted for more than 12 
months.  
d. Permanent  – Persistent atrial fibrillation where a joint decision by [CONTACT_659627] a rhythm control strategy.  
e. Non valvular Atrial fibrillation – AF in the absence of rheumatic mitral stenosis, a 
mechanica l valve  
 
[IP_ADDRESS]  Atrial Fibrillation Diagnosis  
a. Know n past medical history of atrial fibrillation (as documented in patient’s medical 
record)  
b. Newly diagnosed atrial fibrillation lasting at least 10 seconds as documented by 12 -lead 
electrocardiogram, rhythm strip, telemetry monitoring, Holter/event recorder monitoring.  
c. Pacemaker/ICD/implantable loop recorder interrogation – Electrograms must be u sed to 
make the diagnosis (marker channels and mode switch epi[INVESTIGATOR_659588]).  Electrograms should be reviewed by a member of the Atrial Fibrillation Adjudication Committee  
 
3 STUDY OBJECTIVES  
3.1 Research Hypothesis  
Early anticoagulation treatment regimen with Api[INVESTIGATOR_350058] 0 -3 days after TIA, 3 -5 days 
after small ischemic stroke and 7 to 9days after medium ischemic stroke for patients with 
atrial fibrillation  will result in a decreased incidence for recurrent ischemic stroke and 
without significant increase in risk of  intracranial hemorrhage compared to conventional 
treatment for TIA, small and medium sized strokes.  
 
3.2 Primary Objective  
In patients with atrial fibrillation with recent cerebral ischemic symptoms (0 -48 hours), to 
evaluate whether the treatment regimen with Api[INVESTIGATOR_3822] (Three subgroups: TIA: day 0- 3; 
small stroke: day 3 -5; medium stroke: day 7- 9) compared with standard of care treatment 
regimen with warfarin (Three subgroups: TIA: day 7±5; Small or medium stroke: day 
14±5) reduces the composite endpoint of fatal stroke, recurrent ischemic stroke or TIA at 
30 and 180 days. (See figure 1)  
 
3.3 Secondary Objectives 
In patients with atrial fibrillation with recent cerebral ischemic symptoms (0 -48 hours), 
to evaluate whether the treatment regimen of early Api[INVESTIGATOR_3822] (Three subgroups: TIA: 
day 0 -3; small stroke: day 3 -5; medium stroke: day 7-9) compared with standard of care 
treatment with warfarin ( three  subgroups: TIA: day 7±5; Small or medium stroke: day 
14±5) does not increas e the number of intracranial hemorrhage assessed by [CONTACT_9268]/CT by 
30 and 180 days. 
Page 14 of 47  
 
Protocol version 11 version date 07/13/2020  
Additional information will be collected on: 
o Quality of Life  
o Modified Rankin Score 
o NIH Stroke Scale  
o Echocardiography 
o AF Burden (Event Monitor data ). 
     
[ADDRESS_889566] of  initiation of API[INVESTIGATOR_659589] 0 -3 (TIA), days 3- 5 (small stroke) and 
days 7 -9 (medium stroke) to  decrease fatal and/or  recurrent stroke /TIA in  [ADDRESS_889567] suffered a  recent ( 0 to 48 hours from symptoms)  TIA, or small to medium ischemic 
stroke  as defined by [CONTACT_659628] 13.[ADDRESS_889568] of care warfarin  treatment regimen .  
Subjects wi ll be randomly assigned in a 1:1 ratio to one of two treatment arms (api[INVESTIGATOR_157284]). Subjects will be followed for a total of 180 days  from screening through follow-up.  
 
 
 
 
Figure 1 

Page 15 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889569].  Labs to assess liver and kidney function and an EKG will be obtained from the patients’ hospi[INVESTIGATOR_659590].  A 
physical exam will be obtained at screening and at various points throughout the study.  
The screening and baseline/randomization visit may be combined as long as all 
inclusion/exclusion criteria have  been met prior t o randomization.  Otherwise, if these reports 
are not available at the time of screening then randomization and study initiation can  be 
combined into one visit.  
 
 
4.[ADDRESS_889570] will be approximately 180 days. The a ctive treatment phase is 
dependent on the  dosing category (TIA, s mall or medium ischemic stroke) that the subject is 
placed in and which treatment regimen the patient is randomized into.  
 
4.2.2 Total Number of Study Sites/Total Number of Subjects 
Projected  
The study will be conducted at University of South [LOCATION_012] ( USF Health’s  South Center for 
Advanced Health Care, USF Health’s Morsani Center for Advance Health Care , Tampa 
General Hospi[INVESTIGATOR_307] ), University of Louisville ( hospi[INVESTIGATOR_317507] ), University of [LOCATION_004] Los 
Angeles (hospi[INVESTIGATOR_317507]), and Bayfront Cardiovascular Sciences for a total of 4 enrolling 
sites.   
 
Recruitment will stop when approximately 120 subjects meeting eligibility  criteria are 
enrolled.  To account for  drop- outs as well as screen -failures up to 125 subjects will be 
consented  and randomized.  
 
 
4.3 Study Population  
 Adult patients with the diag nosis of atrial fibrillation and  recent TIA or  ischemic small to 
medium stroke  . Recent TIA will be defined as up to 3 days from signs and symptoms, recent 
small stroke will be up to 5 days from signs and symptoms and recent medium stroke will up to 9 days from signs and symptoms. 
4.3.1 Inclusion Criteria   
 
1. Signed Written Informed Consent 
• Before any study procedures are performed, subjects will have the details 
of the study described to them, and they will be given a written informed consent document to read. Then, if subjects consent to participate in the 
study, they will indicate that consent by [CONTACT_2960] a nd dating the informed 
consent document in the presence of study personnel. 
 
P ag e  1 6  o f  4 7  
 
Pr o to co l  v e r s io n  1 1  v e r s io n  d a t e  07 / 13 / 20 2 0  2 .  M a l e s  a n d  F em a l e s  1 8  y e a r s  o f  ag e  an d  o v e r .  
 
3 .  H i s to ry  o f  N o n v a lv u l a r  A t r i a l  F ib r i l l a t io n  (NVAF )  b y  d o cum en t a t io n  in  th e  
m ed i c a l  h i s t o ry  o r  n ew ly  d i ag n o s ed  n o n v a lv u l a r  A t r i a l  F ib r i l l a t io n  a t  t im e  o f  
s tu d y  r an d om i z a t io n  b y  ECG ,  d ev i c e  o r  t e l em e t ry  ( s e e  s e c t io n  2 . 4 . 2 )  
 
4 .  D i ag n o s i s  o f  a  r e c en t  T IA  o r  sm a l l  o r  m ed ium  i s ch em i c  s t r o k e  .  R e c en t  T IA  i s  
d e f i n ed  a s  u p  to  3  d ay s  f rom  s ig n s  a n d  symp tom s ,  r e c e n t  sm a l l  s t r o k e  w i l l  
b e  u p  to  5  d ay s  f r om  s ig n s  a n d  symp tom s  a n d  r e c en t  m e d ium  s t r o k e  w i l l  u p  
to  9  d ay s  f r om  s ig n s  a n d  symp tom s .   (S e e  s e c t io n  2 . 3 . 2 )  
 
5 .  Wom en  o f  ch i ld - b e a r in g  p o t en t i a l  m u s t  u s e  a  r e l i ab l e  m e th o d  o f  co n t r a c e p t io n  an d  
m u s t  p ro v id e  a  n eg a t iv e  p r e g n an cy  t e s t  a t  e n t ry  in to  th e  s tu d y  an d  w i th in  2 4  h o u r s  
o f  s tu d y  t r e a tm en t  in i t i a t io n .   
 
6 .  WOCBP  m u s t  ag r e e  to  fo l l ow  in s t ru c t io n s  fo r  m e th o d ( s )  o f  co n t r a c ep t i o n  fo r  th e  
d u r a t io n  o f  t r e a tm en t  w i th  s tu d y  d ru g  A p ix ab an  p lu s  5  h a l f -l iv e s  ( ap p r o x im a t e ly  3  
d ay s )  p lu s  3 0  d ay s  (d u r a t io n  o f  o v u l a to ry  cy c l e )  f o r  a  t o t a l  o f  3 3  d ay s  p o s t - 
t r e a tm en t  com p l e t io n .  
 
7 .  M a l e s  w h o  a r e  s ex u a l ly  a c t i v e  w i th  WOCBP  m u s t  ag r e e  to  fo l low  i n s t ru c t i o n s  fo r  
m e th o d ( s )  o f  c o n t r a c ep t io n  fo r  th e  d u r a t i o n  o f  t r e a tm en t  w i t h  A p ix ab an  p lu s  5  
h a l f - l iv e s  ( ap p r o x im a t e ly  3  d ay s )  p lu s  9 0  d ay s  (d u r a t io n  o f  sp e rm  tu rn o v e r )  f o r  a  
to t a l  o f  9 3  d ay s  p o s t -t r e a tm en t  c om p l e t io n .  
 
8 .  A z o o sp e rm i c  m a l e s  an d  WOCBP  w h o  a r e  co n t in u o u s l y  n o t  h e t e ro s ex u a l ly  a c t iv e  
a r e  e x em p t  f r om  co n t r a c ep t iv e  r eq u i r em en t s .   H ow ev e r  th ey  m u s t  s t i l l  u n d e rg o  
p r eg n an cy  t e s t in g  a s  d e s c r i b ed  in  th i s  s e c t io n .  
 
I nv e s t ig a to r s  sh a l l  co u n s e l  WOCBP  an d  m a l e  su b j e c t s  w h o  a r e  s e x u a l ly  a c t iv e  w i th  WOCBP  
o n  th e  im p o r t an c e  o f  p r eg n an cy  p r ev en t io n  an d  th e  im p l i c a t io n s  o f  an  u n ex p e c t ed  p r eg n an cy  
I nv e s t ig a to r s  sh a l l  ad v i s e  WOCBP  an d  m a l e  s u b j e c t s  w h o  a r e  s ex u a l ly  a c t iv e  w i t h  WOCBP  o n  
th e  u s e  o f  h ig h ly  e f f e c t iv e  m e th o d s  o f  co n t r a c ep t i o n .  H ig h ly  e f f e c t iv e  m e th o d s  o f  co n t r a c e p t io n  
h av e  a  f a i lu r e  r a t e  o f  <  1%  w h en  u s ed  co n s i s t en t ly  an d  co r r e c t ly .  
A t  a  m in im um ,  su b j e c t s  m u s t  ag r e e  t o  th e  u s e  o f  o n e  m e th o d  o f  h ig h ly  e f f e c t iv e  co n t r a c ep t io n  
a s  l i s t ed  b e low :  
H IGHLY  EFFECT IVE  METHODS  OF  CONTRACEPT ION  
• M a l e  co n d om s  w i th  sp e rm i c id e  
• H o rm o n a l   m e th o d s   o f   co n t r a c ep t io n   in c lu d in g   co m b in ed   o r a l   co n t r a c ep t iv e   p i l l s ,  
v ag in a l  r i n g ,  in j e c t ab l e s ,  im p l an t s  an d  in t r au t e r in e  d ev i c e s  ( IUD s )  su ch  a s  M i r e n a  b y  
WOCBP  su b j e c t  o r  m a l e  s u b j e c t ’ s  WOCBP  p a r tn e r  Fem a l e  p a r tn e r s  o f  m a l e  s u b j e c t s  
p a r t i c ip a t i n g   in   t h e   s tu d y   m ay   u s e   h o rm o n e   b a s ed   co n t r a c ep t iv e s   a s   o n e   o f   t h e  
a c c ep t ab l e  m e th o d s  o f  co n t r a c e p t io n  s in c e  th ey  w i l l  n o t  b e  r e c e iv in g  s tu d y  d ru g   
• IUD s ,  su ch  a s  P a r aG a rd ™ 
• Tu b a l  l ig a t io n  
• V a s e c tom y .  
• C om p l e t e  A b s t in e n c e*  
 
Page 17 of 47  
 
Protocol version 11 version date 07/13/2020 *Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study drugs. Female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be 
discussed in the event that the subject chooses to forego complete abstinence  
 
 
4.3.[ADDRESS_889571] 
enrollment (e.g. GI bleed). 
 
4. History of intracranial bleed   
 
a. Traumatic intracranial bleed within one year of randomization. 
(Traumatic ICH greater than one year of randomization is not an 
exclusion).  
 
5. Current or history of bleeding disorders (e.g. blood dycrasias) 
 
6. Blood Pressure  of 180/100 mmHg  on hypertensive therapy day of randomization 
per PI  [INVESTIGATOR_9106]  20.  
 
7. Current illicit drug use  and/or chronic alcohol use  per PI [INVESTIGATOR_9106] . 
 
8. Severe liver disease (AST/ALT 2x upper limit). 
 
9. Patients with  kidney disease meeting criteria to take 2.5 mg twice daily  who are 
taking strong dual inhibitors of CYP3A4 and P- glycoprotein (e.g. ketoconazole, 
itraconazole, ritonavir, clarithromycin) . 
 
10. Any other suspected etiology for stroke (e.g. ipsilateral carotid disease).  
 
11.  Greater than 3 Cerebral Micro -bleeds (CMB) on gradient recovery echo (GRE) or 
evidence of intracranial hemorrhage on CT at time of randomization . (SWI 
sequencing may be used if GRE sequencing is not obtainable)  
12. Therapeutically anti -coagulated at time of admission (INR at a dmission greater 
than 2.0 on warfarin or took two consecutive doses of NOAC ). 
 
13. Absolute indication for use of warfarin only.( e.g. Mechanical Valve) 
 
14. Absolute indication for anticoagulation prior to randomization window. (e.g. DVT)  
 
15. Hemoglobin less than 9 gm/dl and/or platelet count less than 100 K/uL. 
 
16. Requires dual antiplatelet therapy . 
 
Page 18 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889572] 30 days. 
 
20. Prisoners or subjects who are involuntarily incarcerated. 
 
21. Subjects who are compulsorily detained for treatment of either a psychiatric or 
physical (eg, infectious disease) illness.  
 
22. Concurrent participation in another clinical study where use of an investigational 
product is used  
 Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations of these 
criteria will be reported in accordance with IRB Policies and Procedures.   
4.3.3 Women of Childbearing Potential 
A Women of childbearing potential (WOCBP) is de fined as any female who has experienced menarche 
and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not 
postmenopausal. Menopause is defined as [ADDRESS_889573] a serum follicle stimulating hormone, (FSH) level > 40mIU/mL to confirm menopause. 
*Females treated with hormone replacement therapy, (HRT) are likely t o have artificially suppressed 
FSH levels and may require a washout period in order to obtain a physiologic FSH level. The duration 
of the washout period is a function of the type of HRT used. The duration of the washout period below are suggested guidelines and the investigators should use their judgement in checking serum FSH levels. If the serum FSH level is >40 mIU/ml at any time during the washout period, the woman can be considered postmenopausal : 
• 1 week minimum for vaginal hormonal products (rings, creams, gels)  
• 4 week minimum for transdermal products 
• [ADDRESS_889574] within 24 hours of starting study drug.  Labs to 
assess liver and kidney function and an EKG will be obtained from the patients’ hospi[INVESTIGATOR_659591].   A physical exam  will be obtained at screening.  The scre ening and 
baseline/randomization may be combined as long as all inclusion/exclusion criteria have  been met 
prior to randomization.  Otherwise, if these reports are not available at the time of screening, patients 
Page 19 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889575] in hospi[INVESTIGATOR_659592] a clinic visit.  
5.2 Baseline Visit/ Randomization 
The b aseline/randomization visit will be performed up to 48 hours after signs and symptoms of stroke 
or TIA , and will be combined with the screening visit as long as all inclusion/exclusion criteria have 
met prior to randomization.  
After subjects have been screened and enrolled in the study , baseline assessments will be performed. 
Patients  will be  stratified  according to their type of stroke  ( TIA, small or medium stroke) and 
randomized 1:1 in each group to ensure for equal number of subjects for each three types.  Treatment 
with API[INVESTIGATOR_659593] 5mg or 2.5mg based on clinical characteristics defined in section 1.4  or Warfarin  ( 
target INR 2 -3) will begin based on the randomization  treatment regimen . Study treatment regimen is 
initiated  based off of TIA or stroke  size. Subjects in the Warfarin arm will return to clinic with 
unscheduled INR checks until they reached the standard INR of 2.0 to 3.0. 
Hypertension will be treated  per the AHA/ASA guidelines and are described below:  
Goals for target blood pressure level or reduction from pretreatment baseline are uncertain and  should 
be individualized, but it is reasonable to a chieve a systolic pressure less than 140 mm Hg and a 
diastolic pressure less than 90 mm Hg. For patients with a recent lacunar stroke, it might be reasonable 
to target a systolic blood pressure of less than 130  mm Hg. 20 
Resumption of Blood Pressure therapy is indicated for previously treated patients with hypertension.  
5.3 Treatment Phase   
A study visit for the initiation of treatment will be conducted based on dosing category of TIA, Small 
stroke or medium stroke. See table 2 below and figure 1 : 
 
  Dosing Category  Api[INVESTIGATOR_659576] 0 -3 
Small Stroke  Day 3 -5 
Medium  Stroke  Day 7 -9 
  Dosing Category  Warfarin  dose initiation  window  
TIA Day 7  (+/-5) 
Small Stroke  Day 14  (+/-5) 
Medium Stroke  Day 14 ( +/-5) 
Table 2  
Subjects  will maintain the maximum dose for approximately 180 days (depending on dosing category) 
with study visit s at drug initiation, day 14, 30, 60, 90 , 120, 150 and 180. Patients will undergo drug 
accountability, AE/SAE assessment, and any concomitant medication changes.  
Page 20 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889576]’s individual needs as assessed by [CONTACT_079] [INVESTIGATOR_54720] -Investigator.  
30 day s after the EOS a phone call will be made to assess for AE’s or SAE’s that may have occurred 
during that time frame.   
5.5 Study Assessments (Se e figure 1)  
The NIHSS and mRS Stro ke will b e obtained at screening and days 14, 30, 60, 90, 120, 150 and 180.  
MRI (or CT for subjects with contraindication to MRI) will be obtained at day 14 and EOS or E arly 
Withdrawal (EW) .  
The  Stroke Specific Quality of Life Scale  (SS-QOL)  will be conducted on screening day and again on 
day 30 and at EOS or EW.  
5.6 Unscheduled Visits  
 
5.6.1 Super -therapeutic/Sub- therapeutic INR  
If the subject is not w ithin therapeutic range they  will be expected to return to clinic for an 
unscheduled visit to check the INR value until therapeutic range is met per the warfarin dosing 
protocol . These visits will be scheduled per PI [INVESTIGATOR_9106].  
 
5.6.[ADDRESS_889577]  Completion/ Early Withdrawal 
It will be documented whether or not each subject  completed the clinical study. A subject  is considered 
to have completed the study if he/she has taken all study medications for [ADDRESS_889578] a monthly phone call to 
asses AE/SAE and vital status if they are unable to continue follow -up in clinic .  
 
 
Subjects needing to withdraw prior to the completion of the study and who do not agree to continue in 
follow-up should return to the clinic for completion of early withdrawal procedures, as outlined in 
table 1.  
Reasons that a subject  may discontinue  the study include the following:  
- Adverse events including recurrent stroke or hemorrhagic transformation 
- Intercurrent illnesses  
- Any significa nt new medical condition  
- Protocol violation 
- Non-compliance to study medication regimen  
Page 21 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889579] to follow -up 
- Other (reason to be documented) 
 Withdrawals due to intercurrent illnesses or AEs will be fully documented in the CRF with the addition 
of supplementary information if available and/or appropriate. Withdrawals due to non- attendance will 
be followed-up by [CONTACT_659629]- attendance.  
 
5.[ADDRESS_889580] (e.g., nausea) requiring medication 
management must be approved by [CONTACT_659630].  
 
 
 
6 STUDY PROCEDURES  
 
6.1 Visit 1 Screening Visit /Baseline/Randomization (can occur on same day)  
• Signing an informed consent form prior to any study related activ ities 
• Confirmation of Atrial Fibrillation  either at admission or in subjects medical history  
• Physical exam including vitals  
• Body weight and height 
• Review MRI results to determine diagnosis of TIA or determine size of Ischemic stroke 
• Review of lab s, echocar diogram,  and EKG reports or draw labs and conduct EKG /ECHO if 
needed.  
• Obtain medical history  with demographics 
• Schedule carotid ultrasound or CTA angiogram of the neck if not done at admission  
• Schedule TEE if not done at admission (optional) 
• Review of concomitant medications and procedures 
• Obtain mRS, NIHSS and  SS-QOL scales  
• Urine pregnancy test (for women of childbearing potential) 
• Review of all inclusion/exclusion criteria   
• Treat any patient  with  hypertension  according the current guidelines. (see  se ction 5.2)   
 
6.2 Randomization 
• Confirm subject group selection based of the SACC recommendations, ( TIA, Small ischemic 
stroke, Medium ischemic stroke) and must confirm subjects meets all inclusion criteria and no 
exclusion criteria prior to randomization.  
• Randomize Subject  
• Discuss treatment arm  with patient  
 
6.3 Drug Initiation  (may be same as randomization depending on group and study arm)  
• Urine pregnancy test if not done within 24 hours of this visit  
• Dispense study medication  
Page 22 of 47  
 
Protocol version 11 version date 07/13/2020 • Provide patient education regar ding treatment regimen.  
• Apply event monitor within 14 days from randomization 
• Assess AE/SAE’s  
• Assess concomitant medication  changes  
• Schedule next visit  
• INR for Warfarin arm  
 
6.4 Treatment visits  
Visit day 14 (+/ -3) 
• Physical exam  
• Vital Signs  
• Urine pregnancy test if required  
• ECG  
• NIHSS , mRS  
• MRI or CT scan   
• INR for Warfarin arm  
• Assess Drug Compliance  
• Dispense study medication  
• Provide patient education 
• Assess AE/SAE’s  
• Assess concomitant m edication /procedure changes  
• Schedule next visit  
 
Visit day 30  (+/-5) and 90 (+/ - 10) 
• Physical exam  
• Vital Signs  
• Collect Laboratory assessments including  INR for Warfarin arm  
• Urine pregnancy test if required  
• ECG  
• NIHSS  and mRS  
• SS-QOL only at day 30  
• Assess Drug Compliance  
• Dispense study medication  
• Provide patient education 
• Assess concomitant m edication /procedure changes  
• Assess AE/SAE’s  
• Schedule next visit  
 Visit day 60, 120, 150 (+/- 10) 
• Physical exam  
• Vital Signs  
• Collect INR for Warfarin arm  
• Urine pregnancy test if required  
• ECG  
• NIHSS  , mRS  
Page 23 of 47  
 
Protocol version 11 version date 07/13/2020 • Assess Drug Compliance  
• Dispense study medication  
• Provide patient education 
• Assess concomitant m edication /procedure changes  
• Assess AE/SAE’s  
• Schedule next visit 
 
6.5 End of Study  (+/- 10)  
• Physical exam  
• Vital Signs  
• Collect Laboratory assessments including  INR for Warfarin arm  
• Urine pregnancy test if required  
• MRI or CT scan   
• ECG  
• NIHSS  ,mRS and SS -QOL  
• Assess Drug Compliance  
• Provide patient education 
• Assess concomitant m edication /procedure changes  
• Assess AE/SAE’s  
• Start on non- study Anticoagulation therapy  
 
6.6 Early Withdrawal (EW)  
• Physical exam  
• Vital Signs  
• Collect Laboratory assessments including  INR for Warfarin arm  
• Urine pregnancy test if required  
• MRI or CT scan   
• ECG  
• NIHSS  ,mRS and SS -QOL  
• Assess Drug Compliance  
• Provide patient education 
• Assess concomitant m edication /procedure changes  
• Assess AE/SAE’s  
• Start on non- study Anticoagulation therapy  
 
7  STUDY ENDPOINTS AND EVALUATIONS   
7.1 Primary Endpoint  
Endpoint data will start at randomization up to 180 days. These composite endpoints include:  
• Fatal stroke  
• Recurrent Ischemic stroke  
• New hemorrhagic stroke 
 
 
 
Page 24 of 47  
 
Protocol version 11 version date 07/13/2020 7.2 Secondary Endpoints  
 
• Any intracranial bleeds assessed by [CONTACT_9268]/CT scan at day 14 and EOS or at outcome event .  
• Any major bleeds defined as clinically overt bleeding that was accompanied by [CONTACT_380902]: a decrease in hemoglobin of 2 g/dL or more; a transfusion of 2 or more units of 
packed red blood cells; bleeding that occurred in at least one of t he following critical sites: 
intracranial, intraspi[INVESTIGATOR_1304], intraocular, pericardial, intra-articular,  intramuscular with 
compartment syndrome, retroperitoneal; or bleeding that was fatal. Intracranial hemorrhage 
included intracerebral (hemorrhagic stroke), subarachnoid,  and subdural bleeds.[ADDRESS_889581]  
• Understanding the natural progression of ischemic stroke patients with NVAF within 
the first [ADDRESS_889582] initial stroke event (i.e. stroke or TIA) 
• Effect of the addition of anti- epi[INVESTIGATOR_659594] 
• Factors attributing to the addition of anti-epi[INVESTIGATOR_659595]  
• Factors affecting stroke specific quality of life in patients with embolic stroke secondary to  AF 
 
7.4 Baseline Evaluation (see also schedule of events)  
 
7.4.1 Physical Examination 
A complete medical history including demographic characteristics (age, gender, and race/ethnicity) 
will be collected at screening. Complete physical and neurologic examinations wi ll be performed at 
screening  
7.4.2 Vital Signs 
Heart rate, blood pressure will be performed at every study visit  (temperature, and respi[INVESTIGATOR_659596])  
7.4.3 Laboratory Evaluations  
Evidence of clinical laboratory evaluation within  72 hours of  hospi[INVESTIGATOR_659597].  This will include  Creatinine (CPT [ZIP_CODE] ), complete metabolic panel  (CPT [ZIP_CODE]) , 
complete blood count  with differential and platelets (CPT [ZIP_CODE]),, Lipid Panel (CPT  [ZIP_CODE]) and 
PT/INR (CPT  [ZIP_CODE]),  urine HCG (CPT [ZIP_CODE]) if indicated , aPTT (CPT  [ZIP_CODE] ), TSH (CPT  [ZIP_CODE] ) 
 All WOCBP MUST have a negative pregnancy test within [ADDRESS_889583] be 25 IU/L or equivalent units of HCG. If the pregnancy test is positive, the subject must not receive api[INVESTIGATOR_659598].  
In addition, all WOCB P should be instructed to contact [CONTACT_659631] (e.g., missed or late menstrual period) at any time during study participation.  
See schedule of events  
 
 
7.5 Efficacy and Safety Evaluations (see also schedule of events)  
 
7.5.1 Diagnostic Tests, Scales, Measures, etc.  
 
Page 25 of 47  
 
Protocol version 11 version date 07/13/2020 MRI w/o contrast  (GRE  sequencing preferred  but all effort should be used to maintain the same 
modality of sequencing and magnet strength from baseline  or CT w/o contrast  –  
Will be performed, along with the NIHSS, to measure the size of ischemic stroke at screening. It will 
also be used for follow -up assessments to indicate  any early hemorrhagic transformation or micro -
embolic strokes.  Patients who are unable to have a MRI due to co ntraindication (i.e. implantable 
pacemaker) will have be allowed to use CT with the NIHSS.    
• TIA- will have no ischemic changes  
• Acute infarcts are classified as small, medium or large based on size of the largest ischemic 
lesion:  
 small  = lesion in the anterior or posterior circulation <1.5 cm. 
 medium = equal to or greater than 1.5cm but less than a complete territory 
infarct lesion in a cortical superficial branch of the anterior cerebral artery 
(ACA), middle cerebral artery (MCA), post erior cerebral artery (PCA), or in a 
branch of MCA or PCA, or lesion in internal border-zone territories.  
 large posterior  = lesion involving complete PCA territory,  or lesion of 
cerebellum 1.5 cm or larger or any lesion of the brain stem. 
 large anterior  = lesion involving complete ACA or MCA territory , or lesion 
involving >1 artery territory   
 
• All classifications are based of the measurement of the largest lesion size. 
TEE-  
Will be obtained or scheduled prior to discharge on all patients or will be scheduled as part of their 
evaluation for potential cardiac sources of emboli. In addition to imaging specifically of left atrium thrombus ; measurements will be obtained for left atrial  size, left atrium appendage, velocity, left 
ventricle size and function and other significant myocardial or valvular heart disease.  
 Carotid ultrasound-  
Will be performed on all patients to rule out ipsilateral carotid disease during the screening visit .   
 Laboratory evaluations - 
Will be obtained from all patients at screening, day 30, day 90 and day 180. Additional lab measurements for the warfarin group will be obtained monthly and at unscheduled visits if warranted by [CONTACT_659632] .  
 Event Monitor - 
Will be obtained on all patients in order to characterize the atrial fibrillation burden to assess potential relationship to outcome events. The event monitor be started within 14 days (+3) from randomization 
and maintained for 30 days.  
 
NIH Stroke Scale ( NIHSS )- see appendix 13.2   
Will be used with all patients to provide a rate of worsening, i.e., progression of the index stroke event assessed by [CONTACT_659633]/or an increase in the score on the NIHSS . The 
NIHSS is a [ADDRESS_889584], visual -field loss, extraocular movement, 
motor strength, ataxia, dysarthria, and sensory loss .  The total score can range from 0 -42. The 
breakdown of the scoring is described below:  0 = no stroke  
1-4 = minor stroke 
5-15 = moderate stroke  
15-20 = moderate/severe stroke 
21-42 = severe stroke  
Page 26 of 47  
 
Protocol version 11 version date 07/13/2020  
This scale will be administered at screening /baseline , day 14, 30, 60, 90, 120, 150, 180, and early 
withdrawal .  
  
 
Modified Rankin Scale ( mRS)-
 see appendix 13.1  
Will be used with all patients to  measure severity of stroke and overall disability of patients, this scale 
will also administered on screening /baseline, day 14, 30,  60, 90, 120, 150, 180, and early withdrawal.  
The breakdown of scoring is described below: 
 
Scale  Disability  
0 No symptoms at all  
1 No significant disability despi[INVESTIGATOR_5119] ; able to carry out all usual duties and activities  
2 Slight  disability; unable to carry out all previous activities, but able to look after own affairs without assistance  
3 Moderate  disability; requiring some help, but able to walk without assistance  
4 Moderately severe  disability; unable to walk  without assistance and unable to attend to bodily needs without assistance  
5 Severe  disability; bedridden, incontinent and requiring constant nursing care and attention  
6 Dead  
 
 
 
Stoke Specific Quality of Life Scale (SS -QOL) -See appendix 13.3 
The SS-QOL is a self -report questionnaire consisting of 49 items in the 12 domains of energy, family 
roles, language, mobility, mood, personality, self -care, social roles, thinking, upper extremity function, 
vision, and work/productivity. The domains are scored separately, and a total score is also provided. The 
psychometric properties of the SS -QOL have been validated in patients with ischemic stroke and 
intracerebral hemorrhage . 
 
Physical  
Weight will be recorded in pounds ( lb) and height in inches (in). 
Physical examination will include assessment of the head, eyes, ears, nose, throat, heart, chest, lungs, abdomen, extremities, peripheral pulses, skin and any other physical conditions of note. 
 
Vital Signs  
Blood pressure will be measured in all subjects in either the sitting or supi[INVESTIGATOR_2547].  
 Pregnancy Testing  
Sexually active Women of Child -Bearing Potential (WOCBP) must use an effective method of birth 
control during the course of the study, in a manner such that risk of failure is minimized.  
Before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during 
study participation and the potential risk factors for an unintentional pregnancy. The subject must sign 
an informed consent form documenting this discussion. 
Electrocar diogram (ECG) 
12-lead ECG recordings will be obtained from primary care or performed at screening and examined for 
gross abnormalities.  ECGs will be conducted at various points throughout the study as shown in section 
5  
 Clinical Laboratory Evaluations  
The following labs will be obtained at varies time points in the study as shown in section  6.  
Page 27 of 47  
 
Protocol version 11 version date 07/13/2020 Complete metabolic panel which includes liver enzymes and cre atinine , complete blood count with 
differential and platelets,  PT/INR  and if indicated  urine HCG   
 
  
 
7.5.2 Safety criteria for suspension of dosing  
For subjects experiences adverse events the following criteria will be used to determine whether the 
individual or the entire trial should be discontinued. 
For individual patients 
In the event of a Grade 3 or higher adverse event attr ibutable to treatment with API[INVESTIGATOR_659599], administr ation of API[INVESTIGATOR_659600], alter dosing regimen or to exclude 
the patient from further participation in the study;  if there is any increase  in cerebral microbleeds 
(CMB)  at day 14, in either arm, all study medication will be suspended  until a repeat MRI is 
performed [ADDRESS_889585] descriptive summaries (e.g. 
means and standard deviations for continuous variables such as age and percentages for categorical 
variables such as gender).  Non-parametric analyses will be used in situations where the variables are 
not normally distr ibuted. Baseline comparisons will be performed to test if there is any residual 
unbalance between the treatment and the control groups on demographic and other influential clinical variables.  ANOVA or nonparametric ANOVA will be used to test continuous va riables such as AGE. 
Chi-square or Fisher’s Exact test will be used to test categorical variables such as GENDER. If a 
covariate is unbalanced, it will be included in the regression model for the multivariable analysis as a control variable 
 
8.1.2 Efficacy Analysis/Primary Aim  
For the main outcomes, the proportion of patients with any primary outcome (fatal stroke, recurrent ischemic stroke, transient ischemic attack) will be computed along with the 95% confidence interval for the differences in treatment arms.  
Page 28 of 47  
 
Protocol version 11 version date 07/13/2020  The primary outcome is defined as any component of the composite primary outcome occurred within 
30 and 180 days or otherwise had adequate follow -up.  Logistic regression models will be fitted with 
the primary outcome as the dependent variable and the SUB GROUP: (1) Api[INVESTIGATOR_659601]: day 0 -3; (2). 
Api[INVESTIGATOR_659602]: day 3-5; (3). Api[INVESTIGATOR_659603]: day 7-9; (4) warfarin TIA: day 7±5; (5) warfarin small stroke: day 14±5; (6) warfarin medium stroke: day 14±[ADDRESS_889586] will be assessed by [CONTACT_659634][INVESTIGATOR_659604].  Comparison between individual subgroups will be assessed by [CONTACT_659635]. For example, (1) Api[INVESTIGATOR_659605] (5)  warfarin 
Small stroke: day 14±5.  These analyses will be implemented by [CONTACT_4696] 9.2 PROC LOGISTIC which has the ESTIMATE and the LSMEANS statements for the group comparisons. P<0.05 is used 
for the overall treatment effects. All other subsequent subgroup testing  will be adjusted for multiple 
comparisons by [CONTACT_659636].  
8.1.3 Safety Analysis/Secondary Aim  
The outcome will be measured at 30 and 180 days for all 6 subgroups: all coded as 0 or 1 at both follow-up points. 
The analysis plan for this aim is very similar to that for the Primary Aim except the outcome here is 
defined as intracranial hemorrhage (which is coded as a 0 and 1 variable), and (2) the hypotheses for 
the outcomes are directional and therefore one- sided tests will be performed.  AE incidence will be 
summarized along with the corresponding 95% confidence intervals. 
8.1.4 Potential Confounders  
Age and sex as well as a variety of clinical variables (e.g. CHADS
2-VASc, CHA 2DS 2) that are risk 
factors for embolic stroke, and their associations with fatal or recurrent embolic stroke or hemorrhagic 
cerebral bleed will be examined. Other clinically relevant variables that are shown to differ between 
treatment regimens at enrollment will also be examined as potential confounders.  
 For missing data, both an inte nt-to-treat analysis (in which subjects are analyzed according to their 
randomized assignment) and a per- protocol analysis (in which subjects not treated according to their 
randomized assignment and/or with other major protocol violations are removed from this analysis) 
will be conducted. Sensitivity analyses to assess the effect of missing outcome data on the primary result will be conducted  
8.1.[ADDRESS_889587] is intended to generate data to be used in the deve lopment of 
future, larger studies. A total of 120 patients are expected to be available and eligible to participate in 
this study and up to 125 may be screened in order to yield 120 randomized participants.  
 Review of our database indicates the risk of fatal or recurrent stroke in patients with atrial fibrillation 
is approximately 20% with standard treatment 
9. To calculate expected power in this study, this 
established risk was used as the basis for estimates that could be expected with this treatment if it is 
successful. Given the parameters of conducting a [ADDRESS_889588] with alpha = .05, and equal allocation to 
treatment and control groups (50 patients per group), power calculations were conducted using various 
ratios of outcomes (i.e. fatal or recurrent stroke) in the control group compared to the experimental 
group. The following results were obtained: 
 
Power  Detectable outcome  
Risk in control /  
Risk in experimental  
80% power 2.30 
Page 29 of 47  
 
Protocol version 11 version date 07/13/2020 90% power 2.52 
99% power 3.00 
 
 
8.1.6 Randomization 
Randomization of treatment was calculated in SAS 9.4 using a stratified, blocked PLAN procedure. 
For the 120 subjects to be randomized to either api[INVESTIGATOR_157289], a random seed number was 
generated. Each subgroup of stroke type (small stroke, medium stroke and TIA) was randomized 
implementing block randomization using four blocks of 10. The treatment allocation was created by [CONTACT_659637]. Blinded study envelopes are provided   
to study team members fo r randomization. 
 
8.2 Interim Analysis  
Due the small size and brief duration of the study no interim analyses are planned.  
 
 
9 STUDY MEDICATION  
 Api[INVESTIGATOR_34212] a white to pale-yellow powder. At physiological pH (1.2–6.8), api[INVESTIGATOR_659606]; 
its aqueous solubility across the physiological pH range is ~0.04 mg/mL 
17.  
 Crystalline warfarin sodium  occurs as a white, odorless, crystalline powder that is di scolored by  
[CONTACT_60230]. It is very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and 
ether  
21. 
  
9.1 Packaging 
 
9.1.1 Warfarin   
Will be purchased by [CONTACT_659638].  
 
9.1.2 Api[INVESTIGATOR_659607]:  
 
Product 
Description and 
Dosage Form  Potency  Primary 
Packaging 
(Volume)/ 
Label Type   Appearance  Storage Conditions  
(per label)  
Api[INVESTIGATOR_659608]  2.5 mg  Bottles of 60/  
Marketed label   yellow, round, biconvex, 
film- coated tablets with 
“893” debossed on one 
side and “2½” on the 
other side.  Store at 20°C to 25°C 
(68°F-77°F); excursions 
permitted between 15°C 
and 30°C (59°F-86°F) 
Page 30 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889589] any 2 of the following characteristics:  
 • age ≥80 years 
• body weight ≤60 kg 
• serum creatinine ≥1.5 mg/dL 
 
 
Coadministration with CYP3A4 and P- glycoprotein inhibitors: For patients receiving  
Api[INVESTIGATOR_3822] 5 mg twice daily when Api[INVESTIGATOR_659609] P450 3A4 (CYP3A4) and P- glycoprotein (P -gp) 
(e.g., ketoconazole, itraconazole, ritonavir, clarithromycin), the recommended dose is 2.5 mg twice daily [ patients already taking 2.5 mg twice daily, coadministration of Api[INVESTIGATOR_659610]3A4 and P- glycoprotein should be avoided 
 
If a dose of Api[INVESTIGATOR_157297], the dose should be taken as  
soon as possible on the same day and twice-daily administration should be resumed.  The dose should not be doubled to make up for a missed dose. 
 
9.4 Treatment Compliance and Adherence  
Subjects will be instructed to return all medication bottles (empty or partially used) at each study visit. The number of pi[INVESTIGATOR_659611].  
 
Study medication will be counted to asses s compliance at each clinic visit starting at day 14.  Subjects 
who take between 75% and 125% of the prescribed dose will be considered compliant.  Subjects who 
fall outside this range will be counseled and re-instructed on dosing procedures.  Dose modific ations 
along with the reasons for the modifications will be recorded on the CRF for each visit. 
9.5 Drug Accountability  
Records of study drug receipt and disposition will be maintained by [CONTACT_659639], investigational drug orders, dispensing records, and disposition forms.  These records will Api[INVESTIGATOR_659608]  5 mg  Bottles of 60/  
Marketed label   pi[INVESTIGATOR_8745], oval -shaped, 
biconvex, film -coated 
tablets with “894” 
debossed on one side 
and “5” on the other 
side. Store at 20°C to 25°C 
(68°F-77°F); excursions 
permitted between 15°C 
and 30°C (59°F-86°F) 
Page 31 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889590] under the terms and conditions set forth in this protocol.  The study medication is to be 
prescribed by [CONTACT_659640]. 
 
10 SAFETY MANAGEMENT  
10.1 Clinical Adverse Events  
Clinical adverse events (AEs) will be monitored throughout the study.   
10.2 Adverse Event Reporting  
All AEs that occur will be reporte d to the  IRB. All SAEs will be reported to the IRB in accordance 
with IRB policies. AEs that are not serious will be summarized in narrative or ot her format and 
submitted to the IRB at the time of continuing review.  
 
10.3 Definition of an Adverse Event  
An Adverse Event   
[AE] is defined as any new untoward medical occurrence or worsening of a pre existing medical 
condition in a patient or clinical investi gation subject administered an investigational (medicinal) 
product and that does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for 
examp le), symptom, or disease temporally associated with the use of investigational product, whether 
or not considered related to the investigational product. 
 
• The causal relationship to study drug is determined by a physician and should be used to assess     
• all adverse events (AEs). The causal relationship can be one of the following:  
o Related : There is a reasonable causal relationship between study drug 
administration and the AE.  
o Not Related : There is not a reasonable causal relationship between study drug   
administration and the AE.  
 
• The term “reasonable causal relationship” means there is evidence to suggest a causal relationship.  
• Adverse events can be spontaneously reported or elicited during open -ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be questioned regarding the specific occurrence of one or more adverse events).  
 
10.4 Definition of a Serious Adverse Event (SAE)  
            Serious Adverse Event (SAE)  is any untoward medical occurrence at any dose that:  
• results in death  
• is life -threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)  
• requires inpatient hospi[INVESTIGATOR_312] (see NOTE *: below for exceptions)  
• results in persistent or significant disability/incapacity  
• is a congenital anomaly/birth defect  
• is an important medical event, defined as a medical event that may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_313], based on appropriate medical and scientific 
Page 32 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889591] or may require intervention (e.g., medical, s urgical) to 
prevent one of the other serious outcomes listed above. Examples of such events include but are 
not limited to intensive treatment in an emergency department or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not resu lt in hospi[INVESTIGATOR_059].  
− Potential drug- induced liver injury (DILI) is also considered an important medical event --
see the DILI section below for a definition of a potential DILI event. 
Suspected transmission of an infectious agent (eg, pathogenic or non-pa thogenic) via the study drug is 
an SAE.  
Although pregnancy, overdose, and cancer are not always serious by [CONTACT_8661], these events 
must be handled as SAEs  
*NOTE:  The following hospi[INVESTIGATOR_8609]:  
− A visit to the emergency  room or other hospi[INVESTIGATOR_8610] 24 hours that does not 
result in admission (unless considered an “important medical event” or a life- threatening event)  
− Elective surgery planned before signing consent  
− Admissions as per protocol for a planned medical/surgical procedure  
− Routine health assessment requiring admission for baseline/trending of health status (eg, routine 
colonoscopy) 
− Medical/surgical admission other than remedying ill health state that was planned before study entry. Appropri ate documentation is required in these cases  
− Admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason)  
 
10.4.[ADDRESS_889592]’s written consent to participate in the study, all SAEs, whether related or not 
related to study drug, must be collected, including those thought to be associated with protocol -
specified procedures. All SAEs must be collected that occur during the screening period and within 
[ADDRESS_889593] be collected that relate to any later 
protocol-specific procedure (such as follow -up skin biopsy). 
The investigator should report any SAE occurring after these time periods that is believed to be related to study drug or protocol- specified procedure.  
An SAE report should be completed for any event where doubt exists regarding its status of 
seriousness.  
If the investigator believes that an SAE is not related to study drug, but is potentially related to the conditions of the study (such as withdrawal of previous therapy, or a complication of a study 
procedure), the relationshi p should be specified in the narrative section of the SAE Report Form. 
SAEs, whether related or unrelated to the study drug, and pregnancies must be reported to BMS 
within [ADDRESS_889594] be recorded on the SAE Report Form; Pregnancies on a Pregnancy 
Surveillance Form.  
SAE Email Address: [EMAIL_176]  
SAE Fax Number: [PHONE_188]  
Page 33 of 47  
 
Protocol version 11 version date 07/13/2020 If only limited information is initially available, follow -up reports are required. (Note: Follow- up SAE 
reports should include the same investigator term(s) initially reported.)  
If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes 
available, a follow -up SAE report should be sent within 24 hours to the BMS (or designee) using the 
same procedure used for transmitting t he initial SAE report.  
All SAEs should be followed to resolution or stabilization. 
  
10.4.2  Relationship of SAE to study drug or other intervention  
 
Assessment of Severity  
The severity of each SAE will be assessed as described in the following table:  
 
Assessment  Definition  
1 = Mild : Discomfort noted, but no disruption of normal daily activities; slightly bothersome; relieved 
with or without symptomatic treatment  
2 = Moderate : Discomfort sufficient to reduce or affect normal daily activity to some degree; 
bothersome; interferes with activities, only partially relieved with symptomatic treatment  
 
3 = Severe : Discomfort sufficient to reduce or affect normal daily activity conside rably; prevents regular 
activities; not relieved with symptomatic treatment 
 
For each solicited symptom, the subject  will be asked if they sought medical advice (i.e. contact [CONTACT_4490] a 
member of medical personnel) for this symptom.  
 
Assessment of Causality  
The investigator will attempt to explain each SAE and assess its causal relationship, if any, to the Study 
Medication . The degree of certainty with which an SAE can be attributed to  Study Medication (or 
alternative causes, e.g. natural history of the under lying diseases, concomitant therapy, etc.) will be 
determined by [CONTACT_615782]: 
-Reaction of similar nature having previously been observed with this type of medication. 
-The event having ofte n been reported in literature for similar types of medication.  
 The investigator will assess causality of all AEs, using the following method: 
 
In your opi[INVESTIGATOR_1649], is there a reasonable possibility that the AE may have been caused by [CONTACT_659641]?  
• No.  
o Unrelated : there is no suspi[INVESTIGATOR_177872] a relationship between Study 
Medication and AE, there are other more likely causes and the Study Medication  
is not suspected to have contributed to the AE.  
 
• Yes. 
o  Related : there is suspi[INVESTIGATOR_1884] a relationship between the study medication  and 
AE (without determining the extent of probability); there are no other more likely causes and study medication is suspected to have contributed to the AE.  
 
Page 34 of 47  
 
Protocol version 11 version date 07/13/2020 Events considered related to the study medication  will be further classified as follows:  
 
Probable -- AE cannot be reasonably explained by [CONTACT_1604] (i.e. clinical condition,  
                  environmental/toxic factors or other treatments)  
Possible --  AE can be reasonably explai ned by [CONTACT_1604] (as mentioned above) 
Unlikely -- AE occurs within an unusual time frame of administration of study medication 
 and can also be  reasonably explained by [CONTACT_1604] (as mentioned above)  
Non-serious and serious AEs will be evaluated as [ADDRESS_889595] types of events given their different medical 
nature. If an event meets the criteria to be determined "serious", it will be examined by [CONTACT_659642].  
 
Other possible contributors include:  
-Underlying disease 
-Other medication  
-Protocol required procedure  
-Other cause (specify)  
 
10.4.3  Definition of Severity  
All AEs will be graded if possible by [CONTACT_140069] v4.03 
(CTCAE). The severity of AEs that cannot be graded by [CONTACT_30828] 4.0 will be categorized as 
follows: 
Grade 1 – Transient or mild discomfort; no limitation in activity; no medical intervention/therapy 
required. Grade 2  – Mild to moderate limitation in activity, some assistance may be needed; no or minimal 
medical intervention/therapy required.  Grade 3  – Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospi[INVESTIGATOR_29125]. 
Grade 4  – Extreme limitation in activity, significant assistance required; significant medical 
intervention/therapy required hospi[INVESTIGATOR_27595]. 
Grade 5  – Death.  
 
10.5 IRB/IEC Notification of SAEs  
The i nvestigator will promptly notify the IRB of all SAEs and other unanticipated problems related to 
research using the applicable IRB reporting form(s). External SAEs that are unexpected and related to 
the study intervention will be reported as they are received, within 24 hours of receipt, using the 
External SAE form (if applicable).   
All Serious Adverse Events (SAEs) that occur following the subject’s written consent to participate in 
the study through [ADDRESS_889596] be reported to BMS Worldwide Safety. 
10.5.1  SAE Reconciliation  
The investigator will reconcile the clinical database SAE cases transmitted to BMS Global 
Pharmacovigilance (GPV&E). Frequency of reconciliation will beevery three months and once once 
prior to study database lock. BMS GPV&E will e-mail upon request from the investigator, the 
GPV&E reconciliation report. Requests for reconciliation should be sent to 
[EMAIL_177]. The data elements listed on the GPV&E reconciliation report will be 
Page 35 of 47  
 
Protocol version 11 version date 07/13/2020 used for case identification purposes. If the investigator determines a case was not transmitted to 
BMS GPV&E, the case will be sent immediately  
10.5.2  Follow -up report  
If an SAE has not resolved at the time of the initial report, a follow- up report inclu ding all relevant 
new or reassessed information (e.g., concomitant medication, medical history) will be submitted to 
the IRB. All SAE will be followed until either resolved or stable.  
 
 
10.5.3  Non-Serious Adverse Events 
A nonserious adverse event is an AE not cl assified as serious.  
10.5.4  Non-Serious Event Collecting and Reporting  
The collection of non-serious adverse event (NSAE) information should begin at initiation of study drug. Nonserious adverse event information should also be collected from the start of a placebo lead-
in period or other observational period intended to establish a baseline status for the subjects.  
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they become 
serious. Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study drug, or those that are present at the end of study treatment as appropriate.  
Nonserious Adverse Events are provided to BMS via annual safety reports (if applicable), and 
interim or final study reports.  
 
10.6 Health Authority Reporting (US FDA IND)  
Investigators must adhere to local Health Authority Reporting Requirements. For studies conducted 
under an investigator sponsored US FDA IND, provide details of the following: 
 Any event that is both serious and unexpected must be reported to the Food and Drug Administration 
(FDA) as soon as possible and no later than 7 days (for a death or life- threatening event) or 15 days 
(for all other SAEs) after the investigator’s or institution’s initial receipt of the information.  
 
BMS will be provided with a simultaneous copy of all adverse events filed with the FDA. SAEs should be reported on MedWatch Form 3500A, which can be accessed at: 
http://www.accessdata.fda.gov/scripts/medwatch/
 
 
MedWatch SAE forms should be sent to the FDA at:  
 
MEDWATCH   
[ADDRESS_889597]  
Rockville, MD [ZIP_CODE]- 9787  
Fax: 1-800- FDA -0178 (1- [PHONE_189]) 
http://www.accessdata.fda.gov/scripts/medwatch/  
All SAEs should simultaneously be faxed or e- mailed to BMS at:  
Global Pharmacovigilance & Epi[INVESTIGATOR_34237] -Myers Squibb Company  
Fax Number: 609 -818-3804 
Email: [EMAIL_178]  
Page 36 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889598] Abnormalities 
The following laboratory abnormalities should be captured and reported as appropriate: 
• Any laboratory test result that is clinically significant or meets the definition of an SAE 
• Any laboratory test result abnormality that required the subject to have study drug 
discontinued or interrupted  
• Any laboratory test result abnormality that required the subject to receive specific corrective therapy.  
• It is expected that wherever possible, the clinical rather than the laboratory term will be used by [CONTACT_9673] (eg, use the term anemia rather than low hemoglobin value).  
• Laboratory test abnormalities are provided to BMS via annual safety reports (if applicable), 
and interim or final study reports 
 
10.[ADDRESS_889599] will be permanently 
discontinued in an appropriate manner (eg, dose tapering if necessary for subject safety).  The investigator must immediately notify [EMAIL_179] of this event via the Pregnancy Surveillance Form within [ADDRESS_889600] unless contraindicated by [CONTACT_8663] (eg, x- ray studies). Other appropriate pregnancy follow -
up procedures should be consi dered if indicated.  
 
10.[ADDRESS_889601] be reported as 
SAEs.  
10.10  Drug Induced Liver Injury (DILI)  
Wherever possible, timely confirmation of initial liver -related laboratory abnormalities should occur 
prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting the defined 
criteria, must be reported a s SAEs.  
Potential drug induced liver injury is defined as  
1. AT (ALT or AST) elevation > 3 times upper limit of normal (ULN) 
AND  
2. Total bilirubin > [ADDRESS_889602], without initial findings of cholestasis (elevated serum alkaline phosphatase),  
AND  
3. No other immedi ately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre- existing chronic or acute liver disease, or 
the administration of other drug(s) known to be hepatotoxic  
Page 37 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889603] to a local hospi[INVESTIGATOR_659612], or arrange for urgent care for the next day when medically appropriate. 
 
 
11 STUDY ADMINISTRATION  
 
11.1 Treatment Assignment Methods  
Subjects will be randomized at a 1:1 ratio for each treatment arm.   
11.2 Data Collection and Management 
 
The bio statistic ian will be responsible for design of the randomization scheme, creation of analytical 
databases, and the statistical analysis plan.  The PI  [INVESTIGATOR_659613].  
 
Data review, coding and query processing will be done through interaction with USF and site 
personnel . Queries will be generated in real- time as the data are entered.  
 The cycle of data entry , review, query identification/resolution, and correction occurs over the course 
of the study period until all subjects have completed the study.   
Forms and data collection  
Study personnel will enter subject information and data into  source document worksheets that 
correspond to an electronic database containing all subject study data.  
 It is the investigator’s responsibility to ensure that entries are proper and complete.  
 
11.2.1  Sources of Materials  
Data from study visits will be recorded on clinical research forms (CRF) and entered into a secure 
electronic database. All study records will be kept confidential and each subject will be assigned a 
unique study identification number which will be used on all research records. The identity of patients 
will only be known to site personnel and the PI. Original records will be kept in locked files at each 
site and copi[INVESTIGATOR_659614] a locked drawer in a secure office at the PI’s site. Subject information will not be released without the subject’s written consent except to the IRB, FDA and other regulatory monitoring bodies as necessary.  
Data to be recorded for this study include CT/MRI confirmation of stroke ; EKG, physical exams; vital 
signs; copi[INVESTIGATOR_659615] (if available within previous 6 months); medical 
history; concomitant medications; Records will be retained in secure storage for 7 years after the study concludes.  
Page 38 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889604] ’s clinical  care in any way. All 
participation is voluntary. All data will be kept confidential except as required by [CONTACT_659643] a secure data at each study site . All source documents will be stored in locked cabinets with access only 
for the principal investigator [INVESTIGATOR_6254]- investigators. Subject s will be identified by [CONTACT_659644]. Subject  information will be anonymized in publications and only the 
personnel involved in the studies may  be able to link results with actual subje cts.  
 
11.4 Regulatory and Ethical Considerations 
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by [CONTACT_5787] (ICH) and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the [LOCATION_002] Code of Federal Regulations, 
Title 21, Part 50 (21CFR50). 
The study will be conducted in compliance with the protocol. The protocol, any amendments, and the 
subject informed consent will receive Institutional Review Board/Independent Ethics Committee (IRB/IEC) approval/favorable opi[INVESTIGATOR_8594]. 
All potential serious breaches must be reported to [COMPANY_016] (BMS) immediately. A 
serious breach is a breach of the conditions and principles of GCP in connection with the study or the 
protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of the study or the scientific value of the study.  
Study personnel involved in conducting this study will be qualified by [CONTACT_8640], training, and experience to perform their respective tasks.  
This study will not use the services of study personnel where sanctions have been invoked or where there has been scientific misconduct or fraud (eg, loss of medical licensure; debarment).  
11.4.[ADDRESS_889605] or MRI reads at time of 
admission.  Adult p atients of any race and ethnicity  age  18 years  and older will be included   for this 
study.  
Inclusion of Women and Minorities 
Both male and female subjects will participate in the study.  
There are no existing data supporting or negating significant differences in the effects of the study interventions among race/ethnicity subgroups.  
Inclusion of Children 
This study will not be including children as the diagnosis of non- valvular atrial fibrillation with TIA or 
embolic stoke does not usually occur in this population.  
11.4.[ADDRESS_889606] been well documented with t he risk benefit ratios of anticoagulation 
in the treatment of atrial fibrillation being in favor for using these agents. 15, 20  
Page 39 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889607] 
during fo llowup phase and at study visits after starting API[INVESTIGATOR_659616].   
 
The risks of the other study procedures are generally small. Clinical outcome measures questionnaires  
(mRS, NIHSS, SS -QOL ) are non- invasive and are very similar to standard clinical evaluation.  
 A standard venous blood draw is of minimal risk.  There is a risk of pain at the insertion of the needle; 
this is only for a short time. There are low risks of fainting and infection. All venipunctures will be 
performed by a trained phlebotomist. All precautions will be taken to reduce the risks. No adverse events 
are expected.  
 
 
11.4.[ADDRESS_889608] may not be able to provide inform consent  and a Legal Authorized 
Representative (LAR ) will be used. The PI [INVESTIGATOR_12749]- PI [INVESTIGATOR_659617]. The signed consent form will be kept on file at 
the originating site and each subject  will receive a copy of this document as well. Consent will be 
obtained prior to the initiation of any study related procedures.  
 
11.6 Payment to Subjects/Families  
In the present study there will be no payment to subject s. A small travel stipend will be given to 
subjects as appropriate.  
 
11.7 Publication  
It is expected that the Principal Investigators will submit the data for  publication when the study is 
complete and has been evaluated. 
 
 
 
 
Page 40 of 47  
 
Protocol version 11 version date 07/13/[ADDRESS_889609], and Kannel WB. Atrial fibrillation as an independent risk factor for stroke: 
the Framingham Study. Stroke, 1991, 22: 983-88 
2. Gage BF, Waterman AD, Shannon W, et al. Validation of Clinical Classificatin Schemes for 
Predicting Stroke: Results From the National Registry  of Atrial Fibrillaion . JAMA, 2001, 285;22: 
2864-2870. 
3. Saxena R, Lewis S, Berge, et al. Risk of Early Death and Recurrent Stroke and Effect of Heparin 
in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke 
Trial. Stroke,  2001, 32: 2333-37. 
4. Lip GY and Edwards SJ. Stroke Prevention with aspi[INVESTIGATOR_248], warfarin and ximelagatran in patients 
with non- valvular atrial fibrillatin: A systematic review and meta- analysis. 2006; 118, 321-33 
5. Granger CB, Alexander JH, McMurray JJ, et  al. Api[INVESTIGATOR_659618]. N Eng J Med , 2011, 365;11 981-92 Available from nejm.org.  
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Eng J Med , 2011, 365;10: 883-91. Available from nejm.org.  
7. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus Warfarin in Patients with Atrial 
Fibrillation. N Eng J Med , 2009, 361; 12:  1139-51. Available from nejm.org.  
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrilla tion. N Eng J Med , 2013, 369;  22: 2093-2104. Available from nejm.org.  
9. Connolly SJ, Eikleboom J, Campbell J, et al. Api[INVESTIGATOR_659619]. N Eng J Med, 2011, 364;9: 806-17. Available from nejm.org.  
10. January CT, Wann LS, Alpert JS, et al.  2014 AHA/ACC/HRS Guideline for the Management of 
Patients With Atrial Fibrillation:  Executive Summary.  JACC.  2014  
11. Kernan WN, Ovbiagele B, Black HR. Guidelines for the prevention of Strok e in Patients With 
Storke and Transient Ischemic Attack A guideline for Healthcare Professionals From the 
American Heart Association/American Stroke Association. Stroke, 2014; 45:2130-236. Available 
from http://stroke.ahajournals.com  
12. Martin R C, Labovitz AJ, et al. High Recurrence and Increased Mortality in Ischemic Strokes 
secondary to Atrial Fibrillation . Circ. submitted 2014 
13. Berge E, Abdelnoor M, Sandset PM, et al. Low Molecular weight heparin versus aspi[INVESTIGATOR_659620]: a double -blind randomised study. 
Lancet,  2000;355: 1205-10 
14. Bath PMW, Iddenden R, Bath FJ. Low- Molecular –Weight Heparins and Heparinoids in Acute 
Ischemic Stroke A Meta- Analysis of Randomized Controlled Trials. Stroke , 2000, 31:1770-78.  
15. Easton JD, Lopes RD, Bahit, MC, et al. Api[INVESTIGATOR_659621]: a subgroup analysis of the 
ARISTOTLE trial . Lancet Neurol. 2012 Jun;11(6):503 -11. 
16. Butcher KS, Kate M, Gioia L, et al. Safety and Feasibility of Acute Dabigatran Therapy in Minor 
Ischemic Stroke Patients Without Atrial F ibrillation . [PowerPoint] San Diego, CA: International 
Stroke Conference; 2014 
17. Eliquis
TM (Api[INVESTIGATOR_3822]) package insert. Princeton (NJ): Bristol -Myers Squibb Company; Aug 2014  
18. Mar. Wardlaw, JM, Dennis, MS, Lindley, RI, et al. The validity of a simple clinical c lassification 
of acute ischaemic stroke. J Neurol, 1996; 243:274-79. 
19. Sims, JR, Rezai Ghariai, L, Schaefer, PW,et al. ABC/[ADDRESS_889610], 
perfusion, and mismatch volumes. Neurology, 2009; 72:2104-10 
Page 41 of 47  
 
Protocol version 11 version date 07/13/2020 20. James PA, Oparil S, Carter BL, et al. 2014 Evidence- Based Guidelines for the Management of 
High Blood Pressure in Adults reports from the panel members appointed to the eighth joi nt 
national committee (JNC8). JAMA, 2013 
21. CoumadinTM(Warfarin) package insert. Pi[INVESTIGATOR_659622] (NJ): Bristo -Myers Squibb Company; [ADDRESS_889611]. 
 
 
 
13 APPENDICES  
13.1 Modified Rankin Scale  
 
 
 
Score Descrip tion 
 
0 No symptoms at all 
 
1 No significant di sability despi[INVESTIGATOR_5119]; ab le to carry  out all usu al duties and activities 
 
2 Slight disability; unable to carry  out all previous activities,  but ab le to look af ter own 
affairs without a ssistance 
 
3 Moderate di sability; requiring some h elp, but ab le to walk without assista nce 
 
4 Moderately  severe disabilit y; unable to walk without a ssistance and unable to attend to own 
bodily  needs without assistance 
 
5 Severe di sability; bed ridden, incon tinent and requiring cons tant nursing care and attention 
 
6 Dead  
 
 
 
TOTAL (0 –6):    
 
 
  
 
 
13.2 NIHSS  
NIH Stroke Scale (NIHSS) score is available at: 
http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf  
 
 
 
Page 42 of 47  
 
Protocol version 11 version date 07/13/2020  
  
 
13.3 SS- QOL  
 
 
Scoring:  each  item shall  be scor ed with the following  key 
Total help - C ouldn't do it at all - Strongly  agree [ADDRESS_889612] during the day.  
3. I was too tired to do what I wa nted to do. 
Family  Roles  
1. I didn't join in activities  just for fun with my family. 
2. I felt I was a burden to my family. 
3. My phy sical condition i nterfer ed with my personal li fe. 
Language  
1. Did you have tr ouble speak ing? For exampl e, get stuck, stutter, stammer, or slur your words?    
2. Did you have tr ouble speak ing clearly  enough to use the telephone?  
3. Did other  people have tr ouble in understanding  what you said?  
4. Did you have trouble finding  the word y ou wa nted to sa y? 
5. Did you have to r epeat y ourself  so others  could understand y ou? 
Mobility  
1. Did you have tr ouble w alking? (If pa tient can't walk, go to question 4 and score questions  2-3 as 
1.) 
Page 43 of 47  
 
Protocol version 11 version date 07/13/2020 2. Did you lose your balance when bending over to or reaching f or something?  
3. Did you have tr ouble climbing  stairs?  
4. Did you have to st op and r est more than you would like when  walking or using a wheelchair?     
5. Did you hav e trouble with standing?  
6. Did you have trouble getting out of a chair?  
 
 
Mood  
1. I was discouraged  about  my future. 
2. I wasn't inter ested in other  people or activitie s. 
3. I felt withd rawn from other  peopl e. 
4. I had little confidence in myself. 
5. I was not inter ested in food. 
Personali ty 
1. I was irritabl e. 
2. I was inpatient with other s. 
3. My personali ty has changed.  
Self Care 
1. Did you need  help preparing f ood?  
2. Did you need  help ea ting?  For exampl e, cutting f ood or preparing f ood?  
3. Did you need  help getting  dressed?  For exampl e, putting  on socks or shoes, buttoning buttons, or 
zippi[INVESTIGATOR_007]?  
4. Did you need  help taking a ba th or a shower? 
5. Did you need  help to use the toilet?  
Social  Roles  
1. I didn't go out as often as I would like. 
2. I did my hobbies  and r ecreation for short er periods  of time than I w ould like. 
3. I didn't see as many of my friends  as I would like. 
4. I had sex less often than I w ould like. 
5. My physical c ondition  interfer ed with my social  life. 
Thinking 
1. It was hard f or me to c oncentr ate. 
Page 44 of 47  
 
Protocol version 11 version date 07/13/2020 2. I had tr ouble r emembering things.  
3. I had to write things  down to remember  them.  
Page 45 of 47 
 
Protocol version 11 version date 07/13/[ADDRESS_889613] tr ouble writing  or typi[INVESTIGATOR_007]?  
2. Did you have tr ouble putting on socks?  
3. Did you have tr ouble buttoning buttons? 
4. Did you have tr ouble zippi[INVESTIGATOR_007] a zipper?  
5. Did you have tr ouble opening  a jar? 
Vision  
1. Did you have tr ouble seeing the television w ell enough to enjoy a show? 
2. Did you have tr ouble r eaching  things  because  of poor eyesight? 
3. Did you have tr ouble seeing things  oﬀ to one side?  
Work/Productivity  
1. Did you have tr ouble doing daily work around  the house?  
2. Did you have tr ouble finishing  jobs that you started? 
3. Did you have trouble doing the w ork you used to do? 
TOTAL SCORE 
Reference 
Williams  LS, Weinber ger M, Harris  LE, Clark  DO, Biller  J. Developme nt of a stroke-speci fic quality  of life scale. Stroke 1999 
Jul;30(7):1362 -9. 
 
 
 
 
Page 46 of 47 
 
Protocol version 11 version date 07/13/2020 13.4 Warfarin Dosing Protocol  

Page 47 of 47 
 
Protocol version 11 version date 07/13/2020  
 
 